^
    Back
    Association details:
    Biomarker:EGFR G719S
    Cancer:Colon Cancer
    Drug:ABP 494 (cetuximab biosimilar) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer
    Title:

    Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

    Excerpt:
    ...cells harboring the colon cancer-derived G719S and G724S mutants are responsive to cetuximab therapy in vitro...
    DOI:
    https://dx.doi.org/10.1186%2F1476-4598-13-141